Evaluation of Green Tea as Antioxidant Agent in Management of Oral Lichen Planus

Cairo University40 enrolled

Overview

The study included forty individuals divided into 3 groups. 10 control subjects, 15 oral lichen planus (OLP) patients who were treated with topical corticosteroids and 15 oral lichen planus (OLP) patients who were treated with topical corticosteroids and green tea tablets.

This study included forty individuals divided into 3 groups. Group A; 10 systemically healthy control subjects not receiving medication. Group B; 15 Patients who were previously diagnosed with OLP presented in acute exacerbation were treated with topical corticosteroids; Triamcinolone acetonide (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month. Group C; 15 Patients who were previously diagnosed with OLP presented in acute exacerbation were treated with both topical corticosteroids; Triamcinolone acetonide (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month in addition to green tea tablets 200 mg (Green tea extract 5:1, El Obour For Modern Pharmaceutical Industries) as one tablet a day also for one month.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Oral Lichen Planus

Interventions

green tea tablets (Green tea extract 5:1) 200 mgDRUG

Green tea is a product made from the Camellia sinensis plant. The fresh leaves are used to make medicine. the green tea extract is presented in a form of tablets 200 mg and is taken orally.

Triamcinolone AcetonideDRUG

topical corticosteroids (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month

Eligibility

Sex: ALLMin age: 30 YearsMax age: 68 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Patients presented with painful oral lichen planus lesions * Free of any visible oral lesions other than oral lichen planus * Free of any systemic diseases Exclusion Criteria: * Topical treatment or systemic therapy of OLP for one month before starting the study * Pregnant or breast feeding women * Smokers * Use of corticosteroids or other immunosuppressive drugs

Outcomes

Primary Outcomes

Pain

pain was assessed by visual analogue scale (1-10) 1 indicates better and 10 worse, 1 month after treatment

Time frame: one month after treatment

Secondary Outcomes

Salivary Total Oxidative Capacity

total oxidative capacity was assessed in whole unstimulated saliva by ezyme-linked immunosorbent assay (umol/L) at 1 month after treatment

Time frame: one month after treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.